In-Vivo Cell Therapy, Q3 2026: Deal Making Has Jumped Ahead of Clinical Proof

In-vivo cell therapy is an early optionality bet, and deal making has jumped ahead of clinical validation. This is the full analysis behind our Q3 2026 In-Vivo Cell Therapy Intel Hub, with the data under every slide, as of September 2026. Click any chart, card, or company to see what sits behind it.

Matthew Salomon

September 1, 2026

In-Vivo Cell Therapy Intelligence Report, Q3 2026

Competitive Landscape

In-Vivo CD19 Competitive Map: 91 Programs, 71 Developers

T-cell Engagers Intelligence Report, Q3 2026

The Undruggable Cancer Targets Crossing Into the Clinic

2026 Pharma & Biotech IPOs by Month of Listing

Protein Degraders Intelligence Report, Q3 2026

RNA Intelligence Report, Q3 2026

Competitive Landscape

Cardiometabolic RNA Competitive Map: 84 Programs, 9 Targets

T-cell Engagers Intelligence Report, Q3 2026

Competitive Landscape

In-Vivo CD19 Competitive Map: 91 Programs, 71 Developers

Radiopharma Intelligence Report, Q3 2026

T15 Pharma Buyout Map: 29 Deals, ~$98B, and Who Has Room for More

In-Vivo Cell Therapy Intelligence Report, Q3 2026

I&I Intelligence Report, Q3 2026

GLP-1 and Metabolic Intelligence Report, Q3 2026

Competitive Landscape

Pharma I&I Has Evolved Into a Mechanism Stack

ADC Intel Report, Q3 2026: The Next-Generation Engineering Race

1,838 ADCs: Topo-I and Tubulin Hold 86% of Named Payloads

Competitive Landscape

Alzheimer’s at AAIC 2026: A Mechanism-Selection Meeting

See what your team has been missing

Book a demo Read FAQ